Viliqing® (Entecavir) Charity Drug Assistance Program Officially Launched in Jiangxi Province

On July 1, the launch ceremony of the "Viliqing® (Entecavir) Chronic Hepatitis B Patient Charity Drug Assistance Program," initiated by the Jiangxi Provincial Charity Federation and supported by Qingfeng Pharmaceutical Co., Ltd., was held in Nanchang. More than 60 attendees participated in the event, including Zhu Heping, Vice President of the Jiangxi Provincial Charity Federation, Huang Tianjiang, Deputy General Manager of Qingfeng Pharmaceutical, as well as experts from the project hospitals and registered doctors. The ceremony was hosted by Huang Tianjiang, Deputy General Manager of Qingfeng Pharmaceutical.

In his speech, Zhu Heping, Vice President of the Jiangxi Provincial Charity Federation, stated that the launch of the charity drug assistance program for chronic hepatitis B patients would significantly alleviate the economic burden of medical treatment for impoverished patients in the province. It would also address issues such as poverty caused or exacerbated by illness, playing an important role in strengthening the healthcare safety net and contributing to targeted poverty alleviation.

During the subsequent donation ceremony, Qingfeng Pharmaceutical donated a first consignment of drugs worth 2 million RMB to the Jiangxi Provincial Charity Federation, which in turn presented Qingfeng Pharmaceutical with a certificate of donation. Leaders and expert representatives present at the event awarded plaques to the project hospitals and jointly launched the Viliqing® (Entecavir) Charity Drug Assistance Program by unveiling a crystal ball. After the ceremony, experts from the hospitals provided training to all participants on the project.

Qingfeng Pharmaceutical donated Viliqing® (Entecavir) capsules worth 2 million RMB to the Jiangxi Provincial Charity Federation. This donation will provide free medication for chronic hepatitis B patients from impoverished families in the province for two years, significantly reducing their economic burden. According to the project application process, after being diagnosed at the project hospitals, eligible patients can receive an application form from registered doctors. Upon approval, they can then pick up their medication at the designated distribution points.

It is understood that the charity drug assistance program is one of the key initiatives within the "Charity Healthcare Assistance" project of the Jiangxi Provincial Charity Federation. Hepatitis B Virus Infection: A Global Epidemic with Approximately 93 Million Infected in China, Including 20 Million Chronic Hepatitis B Sufferers Long-term standardized antiviral therapy is currently the primary treatment for chronic hepatitis B. However, the medical costs associated with prolonged use of anti-infection drugs create a significant financial burden for economically disadvantaged patients. Statistics show that among the current impoverished population in China, 42% are impoverished due to illness, making it the leading cause of poverty. More than 10 million people suffer from chronic diseases and major illnesses, making addressing poverty caused or exacerbated by illness a key focus of targeted poverty alleviation efforts. To assist economically disadvantaged chronic hepatitis B patients in our province in receiving timely and standardized treatment, alleviating their suffering, and reducing their financial burdens. In August 2017, Qingfeng Pharmaceutical, in collaboration with the Jiangxi Provincial Charity Federation, launched the "Viliqing® (Entecavir) Charity Drug Assistance Program" to provide two years of free first-line antiviral treatment with Viliqing® Entecavir capsules to chronic hepatitis B patients from low-income families and rural areas in the province. This initiative helps more economically disadvantaged patients receive timely, standardized treatment, enabling them to recover their health and break free from poverty.